top of page

Inflection Biosciences Shortlisted for Best Emerging Biotech at OBN Awards

Dublin, Ireland, September 2, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that it has been shortlisted in the ‘Best Emerging UK Biotech Company’ category at the OBN Annual Awards 2015.

The Best Emerging UK Biotech Company award recognises which emerging biotech company in the UK has the most promise. The category is open to companies less than five years old and includes diagnostics, development and platform technology companies.

About the OBN Annual Awards

The OBN Annual Awards, The UK's Independent Awards Celebrating Excellence in Life Sciences Innovation, is a prestigious awards evening celebrating outstanding achievements in the UK life sciences sector over the preceding year. The winners will be announced at the Awards Dinner on Thursday 1st October at the Ashmolean Museum in Oxford. OBN is the Membership organisation supporting and bringing together the UK’s emerging life sciences companies, corporate partners and investors. Further information is available on OBN’s website

About Inflection Biosciences

Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments was licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit


bottom of page